Figure 3. Tumor growth modulation by CDDP and tetracycline treatment in parental and iRTN-1c MCA205 tumors. (A‒D) Tetracycline (TET) mediated reticulon-1c (Rtn-1c) expression combined with cisplatin/CDDP chemotherapy effects the growth rate of established tumors. 2 × 105 parental MCA205 (A and B) or iRTN-1c MCA205 cells (C and D) were injected s.c. into the flank of C57Bl/6 mice. Once palpable, tumors were treated by a single i.p. injection of 0.25 mg/kg CDDP or vehicle (PBS) (day 0) and tumor growth was monitored with a caliper for 25 d. Normal water (A and C) or 100 µM dose TET (B and D) were added in bibber waters for the duration, starting 7 d prior to the cell injection. Moreover, PBS (A and C) or 0.3 µM tetracycline (B and D) were injected intratumorally on day 0. Experiments were done on groups of n = 5 mice and repeated at least twice. Results are reported as means ± SEM *P < 0.05 (unpaired Student’s t test).